Addressing threats to health care's core values, especially those stemming from concentration and abuse of power - and now larger threats to the democracy needed to advance health and welfare. Advocating for accountability, integrity, transparency, honesty and ethics in leadership and governance of health care.
The academic health IT community has spent the past decade (at least) burying their collective ostrich heads in the sand about the crappy software that is called health IT.
A few, though, have taken on the health IT industry at the heart of bad health IT design (including yours truly, which sadly was not enough to save my own mother from health IT design defects).
Probably the bravest soul on these issues, however, is Penn sociologist Ross Koppel. In a critique of the latest from the medical informatics academic community on reigning in the hazards of this technology, an article by Sittig and Singh at U. Texas, he wrote the following piece in the BMJ:
Download it and read it in its entirety. It makes the point that the solutions to these problems (which I increasingly believe just might be an insoluble, wicked problem without major scope and ambition reductions regarding the use of health IT) must be based on reality.
The reality must start from a firm response not to end users being flummoxed by bad rollouts or by carelessness (user error), but to the issue of products poorly designed from the get-go by their sellers whose primary interest is to make money come hell or high water.
Koppel makes the point that one will not get good results driving a car if that car is designed poorly, with hidden and confusing controls, defective brakes and an engine that overheats and explodes without warning, no matter what post-design interventions take place.
The issues of design flaws and fundamental fitness for purpose need to be blown open in a manner similar to the manner in which drugs and other medical devices are evaluated and regulated. Academia needs to lead the charge, not suggest band aids, however well intentioned those band aids might be.
... In essence, I suggest that these two eminent colleagues tell us to look under the lamppost even though, as the old saying goes, the keys were dropped 70 feet away from the lamppost in the dark. Both Singh and Sittig, of course, are fully aware of the errors listed above,3 4 but (1) they expect that we can detect and understand these problems with error reporting, although many potentially serious errors go undetected (thus, unreported), and when detected, the poor design features that contributed to the error may not be readily apparent. (2) Singh and Sittig tend to attribute those sorts of problems to poor implementation, user errors or lack of access to the technology. They do not seriously question if the software is fit for its purpose.
... In fact, their assumption that HIT software is well designed runs throughout their work. They write about: misused software, unavailable software, poorly
implemented software and malfunctioning software (emphasis added), but what of badly designed software—neither user friendly nor interoperable with systems holding needed patient data? That failure is
not in their purview. They don’t challenge HIT vendors who design the software, or the regulators, who so often serve primarily as HIT industry promoters. Here’s what they write we need to address (my
italics): ‘1) concerns that are unique and specific to technology (e.g., to address unsafe health IT related to unavailable or malfunctioning hardware or software);
2) concerns created by the failure to use health IT appropriately or by misuse of health IT.
I add that such articles tend to confuse policy makers about what truly is needed to solve problems with HIT.
I've had the guts to take on these issues via the legal route after the death of my mother, something that led a number of academic zealots to intone that the incident, in 2010, a decade after my writings on bad health IT began, caused me to lose my objectivity. That perverse reasoning passes for wisdom in certain academic informatics circles. Yet it appears their objectivity about health IT never existed.
I lack respect for paper writers who in effect become apologists for products birthed as dangerous right out of the gate by opportunistic health IT companies. Perhaps the health IT-mediated death of one of their loved ones would wake them up, but I sometimes doubt even that.
This is no mere academic spat. In this case, patient risk and harm worldwide is at issue.
The root of any software problem in healthcare, as I've written before, is at the design level. Trying to work around bad design without facing reality leads to and perpetuates risk, patient harm, clinician disillusionment (e.g., the Medical Societies letter to ONC) and impairment of clinicians trying to take care of patients.
Kudos to Koppel. I hope the repercussions of his challenge to the usual academic fecklessness and special accommodations afforded this unregulated industry are not too severe.
Academics can be feckless towards possible sources of funding, but quite mean to internecine challenges, as Sittig, one of the authors of the challenged piece, was with me in an incident I found out about only because he did not know one of the people to whom he badmouthed me had been a former student I'd mentored.
The announced merger and "tax inversion" of Pfizer and Allergan would be one of the largest corporate marriages in US history. It has drawn more than its share of criticism. For example, per the Los Angeles Times, former US Senator and Secretary of State, and current presidential candidate Hilary Clinton said "this proposed merger, and so-called inversions by other companies, will leave U.S. taxpayers holding the bag."
By creating the world's largest drug company, it could certainly further consolidate the US and global pharmaceutical market and raise already high drug prices. While Pfizer in particular has benefited from US funding of biomedical research, including training of researchers and development of research infrastructure, (see this New Yorker article by John Cassidy) making the company pseudo-Irish may be "unpatriotic," as President Obama said with regard to tax inversions in general (per the Washington Post).
The nature of the merger, creating a company that would be Irish for tax purposes, but effectively run out of the US seems at least intellectually dishonest. (Note that the CEO of its supposedly Irish component, Allergan, works out of Parsippany, NJ (per Bloomberg, here.)
The main beneficiaries of the merger appear not to be patients, or health care providers, or US taxpayers, but top company executives. As John Cassidy wrote,
It's hard to avoid seeing the merger as a cynical move designed to boost Pfizer's stock price and generate a windfall for the company's senior managers....
But the latest settlement by Allergan, which I was just about to write about before the merger was officially announced, is a reminder that the companies are a good fit in one sense. Both have long histories of shady behavior as marked by many legal settlements, and in some cases corporate guilty pleas and convictions.
A former district manager of Warner Chilcott Sales U.S., LLC (Warner Chilcott), a pharmaceutical company based in Rockaway, N.J., pleaded guilty today in U.S. District Court in Boston in connection with a scheme to deceive insurance companies and Medicare so that they would cover the costs of Warner Chilcott’s osteoporosis medications, Actonel and Atelvia.
The idea was to promote two of Warner-Chilcott's products, osteoporosis medicines Actonel and Atelvia, by evading insurance company requirements for physicians to justify their use, given questions about their benefits versus harms, and availability of generic treatments for osteoporosis.
Beginning in 2010 and throughout 2011, Podolsky directed the sales representatives in his district to fill out prior authorizations for physicians who prescribed Actonel and Atelvia using false clinical justifications as to why the patient needed Warner Chilcott drugs and submit them to health insurance companies. In some instances, Podolsky’s sales representatives reviewed patients’ medical charts to get the information necessary to fill out the prior authorizations, in violation of the Health Insurance Portability and Accountability Act (HIPAA). Podolsky also directed sales representatives to utilize a website to submit prior authorizations to insurance companies to disguise their identity as pharmaceutical sales representatives. Podolsky and the sales representatives that he supervised knew that they should not be involved in the preparation or submission of prior authorizations.
But Podolsky was not a lone wolf. At the end of October, 2015, the Boston Globe reported more fully on the scheme, and the large settlement made by Allergan, of which Warner-Chilcott was merely a subsidiary. US Department of Justice allegations involved top leaders of Allergan.
The drug reps bought the doctors lunches, dinners, drinks. They paid for speeches the doctors never made. And in exchange, the doctors prescribed drugs that boosted their sales.
Warner Chilcott, a unit of pharmaceutical giant Allergan PLC, will pay $125 million to settle these and other charges in an agreement announced Thursday by US Attorney Carmen M. Ortiz in Boston.
Ortiz said the company ran an elaborate scheme to prod doctors — including in Massachusetts — to prescribe its drugs in exchange for kickbacks.
Warner Chilcott’s former president, W. Carl Reichel, was charged in federal court for allegedly conspiring to pay kickbacks to physicians, and a Massachusetts physician, Dr. Rita Luthra of Longmeadow, was indicted for allegedly accepting payments.
Warner Chilcott illegally promoted at least seven drugs, including the osteoporosis treatments Actonel and Atelvia.
Court documents show that Warner Chilcott representatives promoted their drugs by wining and dining physicians and giving them money and gifts for participating in medical education events. These events often were held at 'upscale restaurants' and contained 'minimal or no educational component.'
The company made fraudulent requests to the federal government and to insurance companies to boost sales of their drugs, the US attorney’s office said, and employees also made unsubstantiated claims about the drugs’ benefits.
Note that the charges were of actions that went well beyond financial fraud. They included dishonest marketing and kickbacks to physicians. The alleged actions could have harmed patients, by inducing physicians to prescribe unneeded drugs with known adverse effects.
Note further that unlike many other legal settlements about which we have written in the past, this one did not allow the company to escape by just paying some money and then claim that it did not confirm or deny the charges. In this case, the company pleaded guilty.
Warner Chilcott has agreed to plead guilty to health care fraud. It will pay a $23 million criminal fine and $102 million to resolve false claims with state and federal governments. The case was brought by two whistle-blowers.
And as noted above, unlike many other legal settlements which did not entail any negative consequences for those who authorized, directed, or implemented the bad behavior, in this case a top executive (although not the highest executive in the overall corporate structure, and not a current executve) was charged with a crime and apparently actually physically arrested (although he has not been convicted of it, yet.)
Meanwhile, Reichel, the former Warner Chilcott president, was arrested in Boston on Thursday.
Prosecutors say in their indictment that Reichel designed a sales and marketing strategy to entice doctors to prescribe his company’s drugs with free dinners and bogus speaking fees. The physicians paid to give speeches often did not speak at all, and instead enjoyed expensive dinners with sales representatives, the indictment says.
Reichel left Warner Chilcott in 2011, according to a news release.
Furthermore, per a Forbes column, Mr Reichel was allegedly involved up to his proverbial eyeballs.
The Reichel indictment says that, while president of Warner Chilcott’s pharmaceuticals divisions from 2009 to 2011, he directed company sales staff to push physicians’ to prescribe its drugs by throwing money at doctors’ in various ways, such as expensive dinners for doctors and their spouses and 'speaker' fees to attend informal dinners without educational content.
Reichel also allegedly provided sales reps with a separate expense account to buy food and drinks for employees of physicians who prepared prior authorization forms certain insurers required to pay for patients’ drugs.
Reichel hired 'Type A crazy' sales representatives, as he called them, who were provided with 'limited training concerning compliance with health care laws and otherwise de-emphasized the importance of compliance to the sales force,' the indictment says.
Of course, the top executive in the overall corporate structure said the usual, as likely written by his public relations spin doctors,
Brent Saunders, the chief executive of Dublin-based Allergan, said in a statement: 'We take seriously our responsibility and commitment to abide by all US and international laws that govern the sales, marketing, education, and promotion of our products, and recognize the tremendous impact that this responsibility has on the customers and patients we serve.'
Thus this settlement may be regarded as much tougher than many previous legal settlements involving big health care organizations.
However, its bearing on the huge Prizer-Allergan merger has apparently not so far been publicly discussed.
Allergan's Previous Track Record
It is not that the new Allergan settlement is a one-off. It needs to be viewed in the context of Allergan's previous history of misbehavior.
That history may be a bit obscure, especially because of Allergan's complex corporate structure. However, a Wall Street Journal article on the merger provided a bit of Allergan's corporate back story,
Allergan itself is the result of a number of mergers in quick succession. It started off as a generic-drug company called Watson Pharmaceuticals Inc. In 2012, Watson acquired Swiss rival Actavis Group and adopted that name. It also absorbed Warner Chilcott PLC and Forest Laboratories Inc. in multibillion-dollar deals.
Mr. Saunders was CEO of Forest Labs, and became CEO of Actavis after that deal. Shortly after, Allergan’s predecessor was put into play when Valeant Pharmaceuticals International Inc. made an unsolicited offer to buy the California company.
Actavis then stepped in as a white knight and bought Allergan, taking the company’s name.
Allergan and its predecessor companies have an interesting record of misbehavior. Just perusing Health Care Renewal one can find:
- Actavis was convicted and fined more than $170 million in 2011 by a Texas jury of misrepresenting prices to the state's Medicaid program (see this post.)
- In 2010, in case which included allegations that it paid kickbacks to physicians to promote its product, Allergan pleaded guilty to to federal charges of misbranding of Botox and agreed to penalties of about $600 million (see this post).
- In 2010, Forest Laboratories settled allegations that it deceptively promoted drugs, particularly that it promoted anti-depressant Celexa for children by partially by covering up negative trial results about it. This likely hurt patients, since anti-depressants like Celexa have been shown to have severe adverse effects, including suicidal ideation, for children. The company also was charged with giving kickbacks to physicians to promote drugs. The company pleaded guilty to a felony charge of obstructing justice, and two misdemeanors, including misbranding Celexa and illegal distribution of Synthroid. The company paid over $300 million in penalties and submitted to a corporate integrity agreement. (See this post) The Department of Justice threatened to disbar the CEO of Forest Laboratories, but then inexplicably backed off (see this post).
So the latest settlement by Allergan subsidiary Warner Chilcott is the fourth major settlement since 2010. The company and its predecessors have pleaded guilty to crimes, at least once to a felony, and settled cases involving allegations of kickbacks and deceptive marketing practices.
Pfizer's Previous Track Record
And things really get interesting when one considers Pfizer's track record, which seems much sorrier than Allergan's. Our latest post, about Pfizer misbehavior was only one month ago (October, 2015). A UK judge found that the company threatened health care professionals for using a generic competitor.
Many posts on Pfizer can be found here. The latest update of Pfizer's troubles since 2000 follows.
In the beginning of the 21st century, according to the Philadelphia Inquirer, Pfizer made three major settlements,
- In 2002, Pfizer and
subsidiaries Warner-Lambert and Parke-Davis agreed to pay $49 million to
settle allegations that the company fraudulently avoided paying fully
rebates owed to the state and federal governments under the national
Medicaid Rebate program for the cholesterol-lowering drug Lipitor.
- In 2004, Pfizer agreed to pay
$430 million to settle DOJ claims involving the off-label promotion of
the epilepsy drug Neurontin by subsidiary Warner-Lambert. The promotions
included flying doctors to lavish resorts and paying them hefty
speakers' fees to tout the drug. The company said the activity took
place years before it bought Warner-Lambert in 2000.
- In 2007, Pfizer agreed to
pay $34.7 million in fines to settle Department of Justice allegations
that it improperly promoted the human growth hormone product Genotropin.
The drugmaker's Pharmacia & Upjohn Co. subsidiary pleaded guilty to
offering a kickback to a pharmacy-benefits manager to sell more of the
- Pfizer paid a
$2.3 billion settlement in 2009 of civil and criminal allegations and a
Pfizer subsidiary entered a guilty plea to charges it violated federal
law regarding its marketing of Bextra (see post here).
- Pfizer was involved in two other major cases from then to early 2010,
including one in which a jury found the company guilty of violating the
RICO (racketeer-influenced corrupt organization) statute (see post here).
- The company was listed as one of the pharmaceutical "big four" companies in terms of defrauding the government (see post here).
- Pfizer's Pharmacia subsidiary settled allegations that it inflated drugs costs paid by New York in early 2011 (see post here).
- In March, 2011, a settlement was announced in a long-running class
action case which involved allegations that another Pfizer subsidiary
had exposed many people to asbestos (see this story in Bloomberg).
- In October, 2011, Pfizer settled allegations that it illegally marketed bladder control drug Detrol (see this post).
- In August, 2012, Pfizer settled allegations that its
subsidiaries bribed foreign (that is, with respect to the US) government
officials, including government-employed doctors (see this post).
- In December, 2012, Pfizer
settled federal charges that its Wyeth subsidiary deceptively marketed
the proton pump inhibitor drug Protonix, using systematic efforts to
deceive approved by top management, and settled charges by multiple
states' Attorneys' General that it deceptively marketed Zyvox and Lyrica
(see this post).
- In January, 2013, Pfizer settled Texas charges that it had misreported information to and over-billed Medicaid (see this post).
- In July, 2013, Pfizer settled charges of illegal marketing of Rapamune (see this post.)
- In April, 2014, Pfizer settled allegations of anti-trust law violations for delaying generic versions of Neurontin( see this post).
- In June, 2014, Pfizer settled another lawsuit alleging illegal marketing of Neurontin (see this post).
- In 2015, a settlement by Pfizer of a shareholders' lawsuit stemming from charges of illegal marketing was announced (see this post).
So the proposed merger of Pfizer and Allergan would truly create a behemouth of bad behavior. The combined company would have a staggering record of legal settlements, guilty pleas and convictions involving deceptive marketing, fraud, kickbacks, bribes and anti-trust violations, and even an obstruction of justice plea and a RICO conviction. Yet the managers in charge of the two companies when the bad behavior occurred never had to suffer any negative consequences (although in one current case there is the possibility one executive might be convicted). Many of these managers have become amazingly rich during the course of their leadership. Is there any reason to think, absent any unexpected increase in the courage and resolve of government law enforcement, or any unexpected public protest, that the new company will not continue to misbehave as long as its executives are making money from the process?
The Pfizer Allergan merger is the true poster child for the amorality, and consequent dysfunction and decline of modern US and now global health care. As long as top managers of big health care organizations can act with impunity, can avoid all responsibility for their organizations' bad behaviors, and can personally profit wildly from their companies actions, the health care death spiral will continue. Will we continue to cry out in the wilderness, or will anyone else see the writing on the wall?
A musical moment to partially alleviate the gloom. "Your Cheatin Heart" sung by Hank Williams Jr.
It's deja vu all over again. In the spring of 2015, the New England Journal, the most prestigious US medical journal, published a remarkable series of opinion pieces extrolling physician-industry collaborations, and minimizing the significance of resulting conflicts of interest. More remarkable was the extent that the articles' argument were bolstered by logical fallacies (look here).
Doubling down, the New England Journal of Medicine appeared to make its first ever endorsement of a nominee for federal office. On October 28, 2015, the NEJM published an editorial with the almost campaign slogan like title, "Califf for the FDA," which enthusiastically endorsed the current presidential nominee to be Commissioner of the US Food and Drug Administration (FDA). (1) It began, [with italics added for emphasis]
Robert M. Califf, M.D., has been nominated to be the next head of the
Food and Drug Administration (FDA); he currently serves as Deputy
Commissioner for the Office of Medical Products and Tobacco. We think
his confirmation as commissioner should proceed as quickly as possible.
Because the FDA oversees the safety and, in some spheres, the efficacy
of products that constitute about 25% of our economy, the country needs a
strong and experienced leader who can keep the FDA focused on its
And the editorial concluded,
Califf's experience, his proven leadership abilities, his record of
robust research to guide clinical practice, and his unwavering
dedication to improving patient outcomes are unsurpased qualifications
for the post of commissioner of the FDA; we strongly endorse his
nomination and urge the Senate to act favorably on it.
I have never seen this journal, known primarily for publishing
research and scholarly opinion on medicine and health care, publicly
render an opinion about a nomination for a federal position, let alone such an enthusiastic one. A quick
search of the journal revealed that it had taken no position and made no
comment about the nominations of the last three US FDA Commissioners, (Dr Margaret
Hamburg, Dr Andrew von Eschenbach, Dr Lester Crawford, and Dr Mark
McClellan, look here) who were nominated by one Democratic and one Republican President.
Dismissing Concerns about Conflicts of Interest
This fervid endorsement came in the face of some controversy about the nomination, particularly about Dr Califf's previous ties to industry (see this post ). He has participated in many industry sponsored clinical research projects. For example, a 2013 JAMA disclosure statement included 13 commercial research sponsors of his work. It also noted his consultative relationships with 32 commercial firms. We discovered he also had a "board level" conflict of interest, having been a director of Portola Pharmaceuticals, for which he received over $250,000 in 2014 (see this proxy statement). He also had been paid for "educational activities" in previous years, possibly including "drug talks," at least per one blogger. So in my humble opinion, the nomination of Dr Califf could potentially become one of the most significant health care revolving door cases to affect US government.
Such consideration may have influenced Senator Bernie Sanders (I - Vermont), who is currently running for President. In early October he announced he would oppose the Califf nomination.
Furthermore, since our post but before the publication of the NEJM editorial, there have been new revelations. Dr Califf twithdrew as authors from several papers that had been accepted for publication, seemingly violating norms for declaring authorship of scholarly works, (see the Boston Globe here). Dr Califf was revealed to have been a
board member of and consultant to Faculty Connection LLC, which advises
academic researchers "who want to work with industry" about regulatory
submissions (see Intercept.com here)
Yet the Editor of the New England Journal of Medicine dismissed concerns about Dr Califf's industry relationships,
a few concerns have been expressed about his associations with industry, and these concerns may have caused some to withhold support for his nomination.
Like Califf, we believe that our actions should be driven by data, not innuendo. Since 2005, Califf has reported, as an investigator, the outcomes of seven clinical trials sponsored solely by industry in primary publications in major general medical journals. Of these trials, four had a negative outcome (i.e., not favoring the intervention), two favored the intervention, and one, with a factorial design, had a mixed outcome. Given this performance, it is impossible to argue that Califf has a pro-industry bias.
This opinion may yet carry the day. The New York Times reported that
Robert M Califf ... coasted through a confirmation hearing on Tuesday,
with most members of a Senate committee - including some who have been
skeptical about his ties to the pharmaceutical industry - seeming set to
support his candidacy.
This occurred despite one more major revelation that appeared since the editorial was published, but before the hearing. A large pharmaceutical company clinical trial which Dr Califf ran had been criticized as biased in favor of the company's drug by the FDA's own staff and consultants. (see POGO here). And it occurred despite calls by various organizations for the nomination to be turned down, including by Public Citizen and the AIDS Healthcare Foundation (see Medscape here).
Missing the Main Point
However, the NEJM editorial seemed to miss the main point. It revolved around the claim that
It is impossible to argue that Califf has a pro-industry bias.
This was based apparently on an informal evaluation by Dr Drazen of seven of Dr Califf's 1200 publications. So at best this was about the question of pro-industry bias in
However, the controversy is about Dr Califf's nomination as the head of the US government agency that oversees the pharmaceutical, device and biotechnology industries, among others, and tries to assure the safety and effectiveness of drugs, biologics and medical devices, among other responsibilities. The overriding issue is about the risk that his decision making in these capacities could be biased. The real issue is the revolving door, not bias in research.
As we have repeated very recently, the revolving door can be veiwed as a species of conflict of interest. Government officials who can look forward to extremely lucrative
employment in health care industry may be much more
inclined to seem friendly to the industry while in office. Government
officials who were previously paid by industry, and who benefited from
financial interactions with industry, are likely to maintain their
industry mindset and be mindful of their industry friends. But the
concern here is not that this risks biasing future research. The risk
is that a person who previously enjoyed close ties, including close
financial ties to industry is at risk of putting the interests of
industry over those of citizens and patients while running a US
government agency charged with regulating that industry and protecting
the health and safety of those citizens and patients.
The literature makes clear that the revolving door process is a source of valuable political connections for private firms. But it generates corruption risks and has strong distortionary effects on the economy, especially when this power is concentrated within a few firms.
Dr Drazen's editorial never directly addressed that issue. It is one that should still be a concern.
Finally, the effect of the Califf nomination on the FDA has generated considerable public comment. The effect of the New England Journal of Medicine's unprecendented editorial endorsement of the nomination has generated almost no discussion. Only on the 1BoringOldMan blog was there note of the past industry ties of the current NEJM editor inspired their own controversies, and asked "since when is the editorship of the NEJM a position from which to weigh in on such matters?" (look here).
Using the editorship to so weigh in could not only obfuscate the debate about the nomination. It could threaten the mission of a proud medical institution. The NEJM claims a
reputation as the 'gold standard' for quality biomedical research and for the best practices in clinical medicine.
thoughtful, carefully reasoned analyses and interpretations [which] help
you crystallize your own opinions on current topics and findings
Yet the blanket and unprecedented endorsement of the current FDA nominee appears otherwise. We have previously argued that the earlier NEJM opinion pieces on conflicts of interest were based on logical fallacies more than "thoughtful, carefully reasoned analyses and interpretation." In the Editor's apparent haste to defend industry-physician relationships, he risks the reputation and mission of once what was really a gold standard.
1. Drazen JM. Califf for the FDA. N Engl J Med 2015; DOI: 10.1056/NEJMe1513828 (link here)
The New England Journal Series Calling for Rethinking the Problem of Conflicts of Interest
After the New England Journal of Medicine published an editorial and three commentaries earlier this year suggesting that concerns about conflicts of interest in health care may have been overblown, we pointed out that many of their arguments were supported by logical fallacies. The Canadian Medical Association Journal has been publishing a series of news articles about the issue. The latest one, published on November 17, 2015, ended by quoting HCR blogger Roy M Poses MD.
Health Care Corruption
On November 16, 2015, the Corporate Crime Reporter published a front page interview, "Roy Poses on Corruption in American Healthcare," The interview is listed here, and summarized here but the full transcript apparently is not available online, but only in print and via subscription. (Link to interview updated on 19 November, 2015).
Keep in mind that while Mr Bakken founded the company, at age 91, while no longer its leader, he proclaimed, " I stay involved with my company." As such, he remains proud of its mission statement,
In 1960, when corporate mission statements were rare, I wrote one that
has never changed. It remains the company’s guiding principle. There are
six tenets, but the first one is the most important: To contribute
to human welfare by application of biomedical engineering in the
research, design, manufacture, and sale of instruments or appliances
that alleviate pain, restore health, and extend life.
Starting in the 1970s, I met with all new employees, explained our history and mission, and in each of their hands I placed a medallion imprinted with the mission statement. I encouraged them to live by it—at work and at home.
To strive without reserve for the greatest possible reliability and quality in our products; to be the unsurpassed standard of comparison and to be recognized as a company of dedication, honesty, integrity, and service. [ital added]
Apparently, he believes that under the "visionary leadership" and "astute direction" of the current, this mission remains central to the organization.
At Medtronic, we live our mission. It’s the basis for how we behave in relationship to our stakeholders, each other, our communities, and the world. But it also guides our relationships with ourselves. We live the Medtronic Mission every day in truly genuine ways by serving others. I am proud to have a mission that is so deeply woven into the fabric of this company that improves millions of lives throughout the world.
Here’s to dreaming on.
Honesty? Integrity? - the Company's 10 Year Track Record
I hate to disillusion a 91-year old, but in light of the company's last 10 year track record, as discussed on Health Care Renewal, he does appear to be in a dream world.
The company has also made a series of legal settlements of various allegations of infamous behavior, in chronological order...
- We discussed
detailed and vivid allegations that Medtronic had been paying off
doctors starting in 2003.
- Medtronic subsidiary Sofamor Danek settled for $40 million
allegations that it gave kickbacks to doctors in the form of sham
consulting fees and lavish trips (look here).
Medtronic agreed in 2007 to pay about $130 million to
settle consumer suits accusing the device maker of hiding
defects in its defibrillators.
- Medtronic subsidiary Kyphon settled a suit for $75 million
and signed a corporate integrity agreement for allegations that it
defrauded Medicare through a scheme that lead to excessive
hospitalization for patients who received the company's spine surgery
device (link here)
Per the Bloomberg 2014 summary again,
The company agreed to a $268
million settlement of suits in 2010 over allegations that
fractured wires in another line of defibrillators caused at
least 13 patient deaths.
- Medtroinic settled for $23.5 million two other federal lawsuits
alleging it paid kickbacks to encourage physicians to implant its
devices (look here).
In June, we discussed
a settlement Medtronic made of allegations that Medtronic gave
kickbacks (that is, bribes) to doctors to get them to use its cardiac
In April, 2015 we discussed three settlements made by Medtronic:
Its subsidiary EV3 settled old allegations that it coached hospitals
how to overbill the US government for procedures using its products
- The company settled allegations it gave kickbacks to physicians to induce them to use its neuromodulation devices.
- The company settled allegations it lied to the US military about US origins of its devices.
(And by the way, we will not belabor the contrast between the statement's committment to "recognize the personal worth of employees,"
and the gargantuan payments made to certain employees, that is, the top
managers, all who got over $3.5 million in 2014, and the "visionary"
CEO, who got over $12 million, look here. )
Someone needs to wake up Mr Bakken. He may still believe in the mission statement, and wish that it is central to his company. However, the track record seems to suggest that the mission statement has been honored often in the breach.
Perhaps the problem is that Mr Bakken is really much more detached from the company he founded than he now admits. However, I worry that this immensely positive spin suggests that he, like many other health care oragnizational leaders, live in some sort of bubble into which no negative karma is allowed to penetrate. Thus convinced of their own innate goodness, they can provide no check on continuing manifestations of corporate greed, most likely with the solace of the own fortunes they build up.
IMHO, we need to break up these huge health care organizations which have become so big that those who run them cannot be in touch with what really goes on. We need to reestablish the accountablity of leaders, and no longer allow them to get credit for all the good that happens, and dodge responsibility for all the bad. True health care reform would entirely transform health care leadership, so that it can become well-informed, supportive of the mission, unconflicted, less self-interested, honest, and certainly law abiding.
The huge corporations which now dominate global health care are creating amazing records of repeated ethical misadventures. We last discussed multinational Swiss based pharmaceutical manufacturer Novartis' escapades in early 2014. Since then, the legal settlements and other legal findings just keep on coming, capped with a big one in late October, 2015.
We will summarize them in chronological order.
Japanese Health, Labor and Welfare Ministry Found that Novartis Concealed Serious Adverse Effects
In August, 2014, per the Japan Times, but apparently not reported widely outside of that country.
Pharma K.K. said it has failed to report at least 2,579 cases of
serious side effects to the health ministry, including one that was
fatal, related to its drugs for leukemia and other diseases, although
employees were aware of the problems.
Of the total,
1,313 cases were related to Glivec and 514 to Tasigna, both drugs for
leukemia treatment. Another 261 cases involved Afinitor, a cancer drug,
the Japanese unit Swiss drug giant Novartis AG said Friday.
The findings were reported to the Health, Labor and Welfare Ministry the same day.
marketing staff at Novartis Pharma recognized the side effects but
failed to report them to the division in charge, breaking the drug
firm’s internal rules, Novartis Pharma said. They were not fully aware
of the importance of the problem and higher-ranking officials failed to
supervise them properly, it said.
In February, per the PharmaLot blog, the Ministry decided to suspend the company for 15 days, after having issued a business improvement order to it. More details of Novartis' problems in Japan can be found in the Japan Times. I cannot find anything to suggest any one in a position of leadership at Novartis faced any negative consequences as a result, however.
Note that by allegedly hiding adverse effects of its drugs, it is possible that the company's alleged actions led doctors and patients to believe the drugs were safer than they really are, possibly leading to overuse of the drugs and resulting in even more adverse effects. I did not see a discussion of possible patient harm in the discussion of this case.
Novartis Executive Pleads Guilty to Bribing Polish Official
An executive at a pharmaceutical company in Poland who pleaded guilty in a bribery case involving improper payment, works for Novartis, the Swiss drugmaker said on Thursday.
Poland's anti-corruption bureau said on Tuesday two women had appeared in court in a case in which a health fund official was given a tourist trip worth more than $1,000 (620.67 pounds) in exchange for backing the sale of a particular drug.
Both defendants pleaded guilty....
The drug involved was not clear, and the company suggested this was an individual act ("the enquiry relates to an individual and the company is not part of the enquiry.") Why an individual would do something like this if not to advance her career is not clear, however. I cannot find any followup coverage of this, nor anything to suggest the supervisors of the executives involved faced any negative consequences.
Again, by bribing an official to promote a particular drug, this case could have led to overuse of the drug, and potentially to patient harm from the drug's adverse effects.
Novartis Subsidiary Sandoz Settles Allegations that it Misrepresented Pricing Data to US Medicaid
In what the federal government says is the largest such settlement ever reached, Sandoz has agreed to pay $12.64 million to resolve allegations that it misrepresented pricing data on medicines that were provided to the Centers for Medicare & Medicaid Services.
Sandoz, which is owned by Novartis and markets hundreds of generic drugs in the U.S., allegedly misrepresented the average sales price data to Medicare between January 2010 and March 2012, according to a statement from the Office of the Inspector General of the U.S. Department of Health & Human Services.
A Novartis spokeswoman writes that the drug maker did not admit to any liability or wrongdoing. 'Sandoz continues to be committed to providing high-quality, affordable medicines to U.S. patients and conducting business with customers and the government with integrity.' As part of the settlement, Sandoz agreed to provide certification that it established a government pricing compliance program.
As the OIG explains, Medicare uses the pricing data to set payments for most drugs covered under Medicare Part B....
Again, no one who authorized, directed or implemented any price misrepresentation faced any negative consequences. Futhermore, as often occurs in US cases, the company did not admit any wrongdoing, and provided the usual public relations boilerplate about upholding the highest principles, the allegations leading to the settlement notwithstanding.
Express Scripts Settles Allegations that it Accepted Kickbacks from Novartis
Express Scripts has agreed to pay $60 million to resolve allegations by U.S. authorities that a business unit participated in a kickback scheme with Novartis that caused federal health care programs to pay for a medicine based on false claims, according to court documents and a regulatory filing.
The U.S. Department of Justice alleged that Novartis offered patient referrals to Accredo Health Group, which is a specialty pharmacy run by Express Scripts, in exchange for bolstering refills of Exjade, a drug used for reducing excess iron in patients who undergo blood transfusions....
Apparently other lawsuits involving allegations of Novartis payments to other pharmacies are pending. Note that the events alleged in some of these proceedings may have occurred while Novartis was already subject to a so-called corporate integrity agreement,
a key issue to watch is the extent to which a so-called Corporate Integrity Agreement that Novartis signed in 2010 factors into the proceedings. These agreements typically run for five years and require a company to establish an internal compliance program and report violations.
At the time that Preet Bharara, the U.S. Attorney in New York, announced the lawsuits against Novartis two years ago, he called the drug maker a 'repeat offender,' and the lawsuits noted that the violations alleged in the litigation took place before and after the CIA was signed.
Note that the settlement was with Express Scripts, although it involved allegations of misbehavior by Novartis. Note also that this settlement throws into doubt one mechanism now widely used by law enforcement in the US to settle cases involving big corporations, the corporate integrity agreement or defererred prosecution agreement. These are agreements made by corporations not to behave badly again. Yet this case may yet demonstrate that these agreements do not deter future bad behavior.
Again, so far, this settlement did not involve any negative consequences for who may have authorized, directed or implemented the bad behavior either at Express Scripts or Novartis.
Novartis Settles US Allegations of Kickbacks to Enhance Sales of Multiple Drugs
In late October, 2015, a larger settlement, at least in monetary terms, of related issues was announced, per Reuters,
Novartis agreed in
principle to pay $390 million to settle U.S. allegations that it
used kickbacks to speciality pharmacies to push sales of some
drugs, the Swiss company said on Tuesday, hitting third-quarter
Since this case involved hundreds of millions dollars, it got a bit more coverage than the others. For example, Bloomberg provided some more specifics,
The payment covers all claims related to the medicines Myfortic, Exjade, Tasigna, Gleevec and TOBI, the company said. The U.S. had sought as much as $3.3 billion from Novartis for Exjade and Myfortic claims, claiming it had referred patients to specialty pharmacies and paid kickbacks in the form of rebates to get those pharmacies to recommend the drugs to patients and to increase sales.
It is customary in such settlements for them to allow the accused corporation to avoid any admission of guilt, often with some statement that the corporation neither confirms or denies the allegations. In this latest cast, however, while the company issued the usual "neither confirm nor deny" statement, the Novartis CEO appeared to want to deny the allegations despite his willingness to pay so many millions to get them behind him, as per Reuters,
Chief Executive Joe Jimenez told reporters Novartis had made the disputed payments to ensure patients took their drugs, including treatments to prevent rejection of transplanted organs, but U.S. government attorneys disagreed.
'It's something we just believe we want to put behind us,' Jimenez said. Novartis said it neither admitted nor denied liability as part of the settlement.
How the payments or rebates to the pharmacies had anything to do with improving patient adherence is not clear. Mr Jiminez's expertise in improving patient adherence is similarly not clear. Per his official company biograpphy, his education was limited to business school, and before becoming a Novartis executive, he ran the Heinz company, makers of the famous ketchup (look here and here).
Note that if, despite the protestations of the CEO to the contrary, the effect of the company's alleged actions was to over-promote use of the drugs, the results could have been excess adverse effects for patients.
Furthermore, and despite this possibility, per the Wall Street Journal, the CEO also seemed unwilling to agree that the company would change any of its practices beyond paying the money,
Chief Executive Joe Jimenez said the rebates were designed to induce specialty pharmacies to ensure that patients completed a course of medicine. He added that Novartis still used this 'quite common' practice at specialty pharmacies in the U.S.
'We continue to maintain that specialty pharmacies must continue to play a role in ensuring patient adherence,' he said. 'How that is going to play out as to whether we change our behavior or not remains to be seen.'
This suggests that CEO Jiminez really thinks that the company should pay the money and then continue doing what it pleases, based on the rationale that the payments to or discounts given pharmacies were meant to improve patient adherence, not oversell the drugs. This may reflect what he really thinks of what his company ought to be doing for, or to us, that is to or for the patients who take the drugs it manufactures.
Some media coverage did not accurately reflect our position and the seriousness of the Company's commitment to working with the government to ensure our behaviors and interactions with specialty pharmacies meet the highest ethical standards. As such, we want to emphasize the following points:
Novartis will make detailed admissions of fact concerning the Government’s allegations as part of the final settlement.
Any reports suggesting that we are not addressing the Government’s concerns or the particular issues on which the litigation focused was not intended by the Company.
We remain committed to working with the government on corporate integrity obligations, including those relating to specialty pharmacies, and conducting our business in an ethical manner that is fully compliant with the law.
We await the statement of facts. Maybe this statement will prove true, but given that the original statement came from the CEO, to whom the PR people who wrote the satement report, perhaps CEO and former purveyor of ketchup Jiminez meant what he said. As noted in the Modern Healthcare blog,
Patrick Burns, co-director of the Taxpayers Against Fraud Education Fund, a not-for-profit funded by whistle-blowers and law firms that represent them, said he remains skeptical of the company's intentions.
Burns said Jimenez's original statements smack of disrespect for the U.S. Justice Department and the U.S. attorney general.
'It's a level of arrogance and ignorance which is jaw-dropping,' Burns said. 'You have the CEO coming out and brazenly saying we will not even change our practice. I think this really is the time for the attorney general to show her teeth.'
We also await any such dental findings.
This set of misadventures are just the latest in a long series by Novartis. In March, 2014, we noted:
- Italian authorities had fined Novartis and Roche for colluding to promote the use of an expensive opthamologic treatment
- the NY Times published interviews with physicians ostensibly showing how Novartis turned them into marketers for the drug Starlix
- Japanese investigators charged Novartis with manipulating clinical research
- Indian regulators canceled a Novartis import license, charging the company with fraud.
Also, in 2013, Novartis was fined for anti-competitive practices in its marketing of Fentanyl by the European Commission (look here), and in 2011 its Sandoz subsidiary settled allegations of misreporting prices in the US for $150 million (look here) Other Novartis misadventures from 2010 and earlier appear here. So Novartis has quite an impressive, if not infamous record of ethical failures.
Nonetheless, the march of its legal cases continues. Furthermore, after the latest case, the Novartis CEO suggested that he saw no clear need for the company to change its ways, even though his PR people later tried to recast his statements.
So we see that the big health care organizations which now dominate health care globally continue to misbehave, and current legal efforts centering on settlements and fines seem to do nothing to deter continued misbehavior. Maybe it is time to end the impunity of the corporate managers who have become rich while such behavior continues on their watch. Modern Healthcare quoted Mr Burns as saying
the financial penalty in this case didn't seem to be enough to fix the problem. He believes the government needs to begin excluding executives such as Jimenez from federal healthcare programs in order to better get its message across that such behavior won't be tolerated.
In the new PharmaLot blog, Ed Silverman was hopeful that things may really be getting ready to change. He first noted, as we have done many times previously,
Over the years, a parade of drug companies has reached settlements, mostly for paying physicians to favor their medicines or illegally marketing products. Rarely, though, do executives suffer any consequences.
Mostly, the federal government resorts to large fines, even though countless people may have been prescribed medicines unnecessarily — at great expense and sometimes great harm. And drug makers simply treat these penalties as a cost of doing business. The failure to come down harder is sadly reminiscent of the recent financial crisis in which most heads of the biggest banks escaped unscathed.
Lately, however, there are signs the government might be changing its approach toward recalcitrant executives, and such a move is long overdue. After all, if individuals are not held accountable, the senior officials who run these companies have little incentive to play by the rules.
One can only hope, I suppose. But to conclude as I have so many times before....
There seems to be increasing recognition that the continuing rise in US
health care costs is unsustainable, and that these costs are not buying
us good health care. There are calls to avoid unnecessary, and
sometimes harmful care. Yet there is a persistent disconnect between
how continuing dishonest behavior by health care organizations, impunity
of their leaders, and lack of accountability by their board members
fuel rising costs, shrinking access, and bad outcomes for patients.
To truly reform health care, we will have to at least recognize the
causes of the current dysfunction. Recognizing how health care
dysfunction is created by unaccountable, dishonest leadership should
lead to true reform that would promote well-informed, honest,
accountable leadership that puts patients' and the public's health ahead
of personal gain.